S&P 500 6,976.44 ▲ 37.41 (+0.54%)
DOW 49,407.66 ▲ 515.19 (+1.05%)
NASDAQ 23,592.11 ▲ 130.29 (+0.56%)
US Markets Closed

ALZN

Alzamend Neuro, Inc.

Price Chart
Latest Quote

$2.17

Current Price
Previous Close $2.15
Open $2.14
Day High $2.21
Day Low $2.13
Volume 35,135
Fetched: 2026-02-03T12:05:49
Stock Information
Shares Outstanding 3.80M
Cash Equivalents $4.45M
Net Income $-6.47M
Sector Healthcare
Industry Biotechnology
Market Cap $8.25M
EPS (TTM) $-2.67
Exchange NCM
🌐 Visit Website
📊 Custom Metrics & Score
Score: 14/42
Debt to Equity 0.16
Debt to Earnings -0.14
Current Ratio 6.58
Quick Ratio 6.22
Return on Equity -113.78%
Avg FCF Growth 0.55%
FCF Yield -83.26%
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
Date Close Volume
2026-02-02 $2.17 35,200
2026-01-30 $2.15 59,500
2026-01-29 $2.02 77,800
2026-01-28 $2.16 79,400
2026-01-27 $2.18 48,800
2026-01-26 $2.15 72,300
2026-01-23 $2.20 128,100
2026-01-22 $2.28 524,500
2026-01-21 $2.43 80,700
2026-01-20 $2.42 83,400
2026-01-16 $2.35 83,900
2026-01-15 $2.25 19,800
2026-01-14 $2.27 24,200
2026-01-13 $2.37 63,900
2026-01-12 $2.33 45,100
2026-01-09 $2.39 84,100
2026-01-08 $2.34 41,600
2026-01-07 $2.34 124,100
2026-01-06 $2.13 44,000
2026-01-05 $2.05 71,000
About Alzamend Neuro, Inc.

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

📰 Latest News
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Zacks â€ĸ 2026-01-26T14:40:01Z
Article thumbnail
EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?
Zacks â€ĸ 2025-11-20T12:50:00Z
Article thumbnail
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants
Benzinga â€ĸ 2025-11-19T12:30:15Z
Article thumbnail
EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants
Benzinga â€ĸ 2025-05-13T11:30:25Z
Article thumbnail
EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program
Benzinga â€ĸ 2025-05-07T11:31:26Z
Article thumbnail
Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks â€ĸ 2025-04-08T13:55:04Z
Article thumbnail
Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March?
Insider Monkey â€ĸ 2025-03-28T14:42:25Z
Article thumbnail
EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025
Benzinga â€ĸ 2025-02-25T12:30:19Z
Article thumbnail
EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels
Benzinga â€ĸ 2025-02-19T12:30:21Z
Article thumbnail
Income Statement (Annual)
Revenue
Metric 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Total Revenue $0 $0 $0 $0
Operating Revenue $0 $0 $0 $0
Expenses
Metric 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Interest Expense $18,029 $10,101 $7,701 $46,524
Total Expenses $4,496,824 $9,937,645 $14,870,466 $12,319,535
Net Non Operating Interest Income Expense $-18,029 $-10,101 $-7,701 $-46,524
Interest Expense Non Operating $18,029 $10,101 $7,701 $46,524
Operating Expense $4,496,824 $9,937,645 $14,870,466 $12,319,535
Selling And Marketing Expense $347,295 $247,334 $742,601 $17,654
General And Administrative Expense $2,734,601 $3,235,204 $6,682,008 $7,100,567
Other Income Expense - - - $4,000
Income & Earnings
Metric 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Net Income From Continuing Operation Net Minority Interest $-4,514,853 $-9,947,746 $-14,878,167 $-12,362,059
Net Interest Income $-18,029 $-10,101 $-7,701 $-46,524
Normalized Income $-4,514,853 $-9,947,746 $-14,878,167 $-12,366,059
Net Income From Continuing And Discontinued Operation $-4,514,853 $-9,947,746 $-14,878,167 $-12,362,059
Total Operating Income As Reported $-4,496,824 $-9,937,645 $-14,870,466 $-12,319,535
Net Income Common Stockholders $-5,105,084 $-9,947,746 $-14,878,167 $-12,362,059
Net Income $-4,514,853 $-9,947,746 $-14,878,167 $-12,362,059
Net Income Including Noncontrolling Interests $-4,514,853 $-9,947,746 $-14,878,167 $-12,362,059
Net Income Continuous Operations $-4,514,853 $-9,947,746 $-14,878,167 $-12,362,059
Pretax Income $-4,514,853 $-9,947,746 $-14,878,167 $-12,362,059
Operating Income $-4,496,824 $-9,937,645 $-14,870,466 $-12,319,535
Special Income Charges - - $0 $4,000
Interest Income - - - $0
Interest Income Non Operating - - - $0
Per Share Metrics
Metric 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Diluted EPS $-11.32 $-132.33 $-228.90 $-189.00
Basic EPS $-11.32 $-132.33 $-228.90 $-189.00
Other
Metric 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-4,446,084 $-9,886,905 $-14,847,400 $-12,315,986
Reconciled Depreciation $50,740 $50,740 $23,066 $3,549
EBITDA (Bullshit earnings) $-4,446,084 $-9,886,905 $-14,847,400 $-12,311,986
EBIT $-4,496,824 $-9,937,645 $-14,870,466 $-12,315,535
Diluted Average Shares $450,799 $75,174 $65,012 $65,996
Basic Average Shares $450,799 $75,174 $65,012 $65,996
Diluted NI Availto Com Stockholders $-5,105,084 $-9,947,746 $-14,878,167 $-12,362,059
Preferred Stock Dividends $590,231 - - -
Research And Development $1,414,928 $6,455,107 $7,445,857 $5,201,314
Selling General And Administration $3,081,896 $3,482,538 $7,424,609 $7,118,221
Other Gand A $964,624 $1,117,360 $1,276,507 $1,225,733
Insurance And Claims $259,382 $381,737 $587,427 $714,329
Salaries And Wages $1,510,595 $1,736,107 $4,818,074 $5,160,505
Total Unusual Items - - $0 $4,000
Total Unusual Items Excluding Goodwill - - $0 $4,000
Other Special Charges - - - $-4,000
Fetched: 2026-02-02
Balance Sheet (Annual)
Assets
Metric 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Net Tangible Assets $3,968,222 $-2,594,185 $3,045,503 $13,351,511
Total Assets $4,602,983 $631,588 $5,915,625 $14,516,443
Total Non Current Assets $425,606 $176,346 $79,843 $102,909
Current Assets $4,177,377 $455,242 $5,835,782 $14,413,534
Prepaid Assets $228,719 $79,194 $694,923 $349,723
Cash Cash Equivalents And Short Term Investments $3,948,658 $376,048 $5,140,859 $14,063,811
Cash And Cash Equivalents $3,948,658 $376,048 $5,140,859 $14,063,811
Cash Financial $3,948,658 $376,048 $5,140,859 $14,063,811
Receivables - - - $0
Current Deferred Assets - - - -
Other Receivables - - - -
Accrued Interest Receivable - - - -
Notes Receivable - - - -
Debt
Metric 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Total Debt - $300,714 - -
Current Debt And Capital Lease Obligation - $300,714 - -
Current Debt - $300,714 - -
Other Current Borrowings - - - -
Liabilities
Metric 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Total Liabilities Net Minority Interest $634,761 $3,225,773 $2,870,122 $1,164,932
Total Non Current Liabilities Net Minority Interest $0 $0 $0 $0
Current Liabilities $634,761 $3,225,773 $2,870,122 $1,164,932
Current Notes Payable $0 $300,714 $0 -
Payables And Accrued Expenses $634,761 $2,925,059 $2,870,122 $1,164,932
Payables $634,761 $2,925,059 $2,870,122 $1,164,932
Accounts Payable $634,761 $2,925,059 $2,870,122 $1,162,850
Equity
Metric 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Common Stock Equity $3,968,222 $-2,594,185 $3,045,503 $13,351,511
Total Equity Gross Minority Interest $3,968,222 $-2,594,185 $3,045,503 $13,351,511
Stockholders Equity $3,968,222 $-2,594,185 $3,045,503 $13,351,511
Retained Earnings $-58,535,261 $-54,020,408 $-44,072,662 $-29,194,495
Other Equity Interest - - $-14,883,295 $-14,883,295
Preferred Stock Equity - - - -
Other
Metric 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Ordinary Shares Number $778,732 $76,444 $71,807 $70,727
Share Issued $778,732 $76,444 $71,807 $70,727
Tangible Book Value $3,968,222 $-2,594,185 $3,045,503 $13,351,511
Invested Capital $3,968,222 $-2,293,471 $3,045,503 $13,351,511
Working Capital $3,542,616 $-2,770,531 $2,965,660 $13,248,602
Total Capitalization $3,968,222 $-2,594,185 $3,045,503 $13,351,511
Additional Paid In Capital $62,503,405 $51,426,215 $62,001,395 $57,419,753
Capital Stock $78 $8 $65 $9,548
Common Stock $78 $8 $65 $9,548
Preferred Stock $0 $0 $0 $0
Net PPE $425,606 $176,346 $79,843 $102,909
Treasury Shares Number - $0 - -
Dueto Related Parties Current - - $0 $2,082
Fetched: 2026-02-02
Cash Flow Statement (Annual)
Free Cash Flow
Metric 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Free Cash Flow $-6,868,186 $-8,417,236 $-8,923,152 $-6,720,448
Operating Activities
Metric 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Operating Cash Flow $-6,568,186 $-8,269,993 $-8,923,152 $-6,613,990
Cash Flow From Continuing Operating Activities $-6,568,186 $-8,269,993 $-8,923,152 $-6,613,990
Operating Gains Losses - - - $-4,000
Investing Activities
Metric 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Capital Expenditure $-300,000 $-147,243 - $-106,458
Investing Cash Flow $-300,000 $-147,243 $0 $-106,458
Cash Flow From Continuing Investing Activities $-300,000 $-147,243 $0 $-106,458
Net Other Investing Changes - - - -
Financing Activities
Metric 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Issuance Of Capital Stock $10,440,196 $3,352,425 $0 $18,911,456
Financing Cash Flow $10,440,796 $3,652,425 $200 $18,854,989
Cash Flow From Continuing Financing Activities $10,440,796 $3,652,425 $200 $18,854,989
Net Preferred Stock Issuance $7,736,144 $2,100,000 $0 -
Preferred Stock Issuance $7,736,144 $2,100,000 $0 -
Net Common Stock Issuance $2,704,052 $1,252,425 $0 $18,911,456
Common Stock Issuance $2,704,052 $1,252,425 $0 $18,911,456
Net Other Financing Charges - - - -
Other
Metric 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Issuance Of Debt $0 $300,000 $0 $0
End Cash Position $3,948,658 $376,048 $5,140,859 $14,063,811
Beginning Cash Position $376,048 $5,140,859 $14,063,811 $1,929,270
Changes In Cash $3,572,610 $-4,764,811 $-8,922,952 $12,134,541
Proceeds From Stock Option Exercised $600 $0 $200 $2,200
Net Issuance Payments Of Debt $0 $300,000 $0 $-58,667
Net Short Term Debt Issuance $0 $300,000 $0 -
Short Term Debt Issuance $0 $300,000 $0 -
Net PPE Purchase And Sale $-300,000 $-147,243 $0 $-106,458
Purchase Of PPE $-300,000 $-147,243 $0 $-106,458
Change In Working Capital $-2,438,467 $670,666 $2,349,324 $1,327,181
Change In Payables And Accrued Expense $-2,288,942 $54,937 $1,707,272 $693,584
Change In Prepaid Assets $-149,525 $615,729 $642,052 $633,597
Other Non Cash Items $9,286 $714 - $12,770
Stock Based Compensation $325,108 $955,633 $3,582,625 $4,408,569
Depreciation Amortization Depletion $50,740 $50,740 $23,066 $3,549
Depreciation And Amortization $50,740 $50,740 $23,066 $3,549
Depreciation $50,740 $50,740 $23,066 $3,549
Net Income From Continuing Operations $-4,514,853 $-9,947,746 $-14,878,167 $-12,362,059
Repayment Of Debt - - $0 $-58,667
Net Long Term Debt Issuance - - $0 $-58,667
Long Term Debt Payments - - $0 $-58,667
Long Term Debt Issuance - - - $0
Fetched: 2026-02-02